Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CanSino Biologics, Inc. Class H ( (HK:6185) ) has issued an update.
CanSino Biologics Inc. has announced its audited consolidated annual results for the year ending December 31, 2024. The results, which comply with the Hong Kong Stock Exchange’s listing requirements, have been reviewed and confirmed by the company’s board and audit committee. The annual report will be available to shareholders and on relevant websites, reflecting the company’s commitment to transparency and regulatory compliance.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of innovative vaccines. It operates within the biopharmaceutical industry, targeting global markets with its vaccine products.
YTD Price Performance: 9.05%
Average Trading Volume: 1,343,043
Technical Sentiment Signal: Sell
Current Market Cap: HK$10.4B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.